Pure Global: Brazil's AI MedTech Approval - Hacking ANVISA's New Digital Maze.

Brazil's regulatory agency, ANVISA, is launching a major digital overhaul for 2026, promising to slash approval times and streamline market access for medical devices. This episode dives into the core of ANVISA's new agenda, from the 'AnvisAI' project aimed at modernizing submissions to new fast-track queues for lower-risk devices. We explore how this digital transformation is creating unprecedented opportunities for MedTech innovators. For instance, a company with a cutting-edge AI diagnostic tool that once faced a multi-year waiting period now sees a viable path to market, evidenced by recent approvals of complex software. But this new speed comes with higher expectations, demanding alignment with stringent global standards. Key Questions This Episode Will Address: - How will ANVISA's 2026 digital agenda change your market entry strategy for Brazil? - Is your current technical dossier prepared for the new, stricter compliance framework? - What are the hidden risks of misclassifying your software under the new accelerated pathways? - How can the recent approval of AI imaging software serve as a roadmap for your submission? - Are you prepared to leverage these regulatory changes to get ahead of your competitors in LATAM's largest market? - What specific steps must you take to adapt your Quality Management System for Brazil's new landscape? At Pure Global, we provide end-to-end regulatory consulting to help MedTech and IVD companies navigate this evolving environment. We combine local expertise with advanced AI tools to streamline global market access. Let us be your local representative and strategic partner in over 30 markets. Contact us for a consultation at [email protected] or visit https://pureglobal.com/.